Novartis: Positive top line results of BOLERO-3: to be confirmed at the ASCO congressBUY, Fair Value CHF77 (+7%)
Novartis revealed yesterday the top line results of BOLERO-3 studying Afinitor plus Herceptin (and vinorelbine) in 2nd Line of treatment in HER2 positive advanced breast cancer. At this step, we only know that the combination of these drugs significantly extended PFS after prior therapy when compared to treatment with placebo plus Herceptin and vinorelbine. All the details will be presented in the ASCO congress from 31st to 4th June.
Full report available to subscribers
Please contact firstname.lastname@example.org